查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618644

抗药性金黄色葡萄球菌治疗市场：按药物类型、给药途径和销售管道划分 - 全球预测 2025-2030

Methicillin-Resistant Staphylococcus Aureus Drugs Market by Agent Type (Ceftaroline, Daptomycin, Linezolid), Route of Administration (Oral, Parenteral), Sales Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗药性金黄色葡萄球菌治疗市场规模为20.9亿美元，预计2024年将达22.1亿美元，复合年增长率为6.39%，2030年将达32亿美元。

抗药性金黄色葡萄球菌(MRSA) 治疗市场专注于针对 MRSA 引起的感染疾病的特定治疗，MRSA 是一种对多种抗生素具有抗药性的葡萄球菌。这些药物的需求之所以出现，是因为抗甲氧西林金黄色葡萄球菌对公共卫生构成了重大挑战，因为它对常见抗生素具有抗药性，导致通常难以治疗的严重感染疾病。应用涵盖各种医疗保健环境，包括医院和门诊诊所，主要用于治疗皮肤感染疾病、肺炎和血液感染疾病。最终用途领域包括医疗保健设施、製药和生技公司。关键的成长要素包括抗生素抗药性感染疾病的流行和医疗保健支出的增加，而分子诊断和药物开发的进步推动了进一步的进展。最近的趋势包括开发新的抗生素和替代疗法，例如噬菌体疗法和免疫疗法。公司应探索与学术机构合作进行药物发现，并投资人工智慧主导的研究以缩短开发週期。市场开拓的限制包括高昂的药物开发成本、潜在的监管障碍以及医疗保健系统整合新 MRSA治疗方法的适应性缓慢。来自政府和医疗保健提供者的经济挑战和价格压力也发挥着重要作用。可以透过专注于多标靶药物开发和利用生物技术来提高现有治疗方法的有效性来推动创新。此外，加强感染控制和病患教育可以最大限度地减少 MRSA 感染并间接影响市场成长。 MRSA 治疗市场的性质是动态的，医学研究的快速进步导致了不断变化的格局。研发方面的策略投资以及最尖端科技的采用对于企业站稳脚跟并有效应对 MRSA 带来的新威胁至关重要。

主要市场统计
基准年[2023] 20.9亿美元
预计年份 [2024] 22.1亿美元
预测年份 [2030] 32.2亿美元
复合年增长率（%） 6.39%

市场动态：快速发展的抗药性金黄色葡萄球菌治疗市场的关键市场洞察

供需的动态交互作用正在改变抗药性金黄色葡萄球菌治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 与抗药性金黄色葡萄球菌相关的感染疾病日益流行
    • 私营和公共部门增加对医疗保健的投资
  • 市场限制因素
    • 抗药性金黄色葡萄球菌治疗药物製剂所用原料成本变化
  • 市场机会
    • 正在进行的研发活动，开发新型抗药性金黄色葡萄球菌治疗方法
    • 抗药性金黄色葡萄球菌治疗的专利到期增加
  • 市场挑战
    • 漫长而严格的监管核准流程

波特五力：开拓抗药性金黄色葡萄球菌治疗市场的策略工具

波特的五力架构是了解抗药性金黄色葡萄球菌治疗市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对抗抗药性金黄色葡萄球菌治疗药物市场的影响

外部宏观环境因素在塑造抗药性金黄色葡萄球菌治疗市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗药性金黄色葡萄球菌治疗药物市场的竞争格局

对抗药性金黄色葡萄球菌治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗药性金黄色葡萄球菌治疗市场供应商的绩效评估

FPNV定位矩阵是评估抗药性金黄色葡萄球菌治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘抗药性金黄色葡萄球菌治疗市场的成功之路

对于希望加强在全球市场的影响力的公司来说，抗药性金黄色葡萄球菌治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 抗药性金黄色葡萄球菌引起的感染疾病盛行率增加
      • 私营和公共部门增加对医疗保健的投资
    • 抑制因素
      • 抗药性金黄色葡萄球菌治疗配方中使用的原料的变动成本
    • 机会
      • 持续研发新开发的抗药性金黄色葡萄球菌治疗药物
      • 抗药性金黄色葡萄球菌治疗药物专利到期数量增加
    • 任务
      • 耗时且严格的监管核准流程
  • 市场区隔分析
    • 药物类型：使用Daptomycin有效治疗 MRSA 的进展
    • 销售管道：由于易于访问，对线上管道的偏好正在增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章抗药性金黄色葡萄球菌治疗药物市场（按药物）

  • 头孢洛林
  • Daptomycin
  • Linezolid
  • 特拉万辛
  • 万古霉素

第七章抗药性金黄色葡萄球菌治疗市场：依给药途径

  • 口服
  • 胃肠外的

第八章抗药性金黄色葡萄球菌治疗药物市场：依销售管道

  • 离线
    • 医院药房
    • 零售药房
  • 在线的

第九章 美洲抗药性金黄色葡萄球菌治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区抗药性金黄色葡萄球菌治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲抗药性金黄色葡萄球菌治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 英国政府策略投资全球抗菌药物抗药性监测，加强亚洲和非洲的卫生系统
    • 瓦西利亚申请 FDA核准新抗生素头孢比普罗对抗 MRSA
    • BARDA 为 Melinta Therapeutics 提供策略性资助倡议，以改善儿科抗生素的获取
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Aridis Pharmaceuticals Inc.
  • Armata Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Cardinal Health, Inc.
  • Cumberland Pharmaceuticals Inc.
  • Debiopharm SA
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Innovation Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Nabriva Therapeutics GMBH
  • Novartis AG
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • R-Biopharm AG
  • Shionogi Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries ltd
  • Theravance Biopharma, Inc.
Product Code: MRR-0363DFE0369A

The Methicillin-Resistant Staphylococcus Aureus Drugs Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.21 billion in 2024, and is projected to grow at a CAGR of 6.39%, to USD 3.22 billion by 2030.

The Methicillin-Resistant Staphylococcus Aureus (MRSA) drugs market focuses on therapeutics specifically designed to combat infections caused by MRSA, a type of staphylococcus bacteria resistant to many antibiotics. The necessity for these drugs arises from the significant challenge MRSA poses to public health due to its resistance to common antibiotics, often leading to severe infections that are difficult to treat. Applications span various healthcare settings, including hospitals and outpatient clinics, primarily addressing skin infections, pneumonia, and bloodstream infections. End-use sectors comprise healthcare facilities, pharmaceuticals, and biotechnology firms. Key growth factors include the rising prevalence of antibiotic-resistant infections and increasing healthcare expenditures, whereas advancements in molecular diagnostics and drug development further drive progress. Recent opportunities are found in the development of novel antibiotics and alternative therapies like bacteriophage treatment and immunotherapy, crucial due to mounting antibiotic resistance. Companies should explore partnerships with academic institutions for drug discovery and invest in AI-driven research to shorten development cycles. Limitations in the market include the high cost of drug development, potential regulatory hurdles, and the slow adaptability of healthcare systems to integrate new MRSA treatments. Economic challenges and price pressures from governments and healthcare providers also play a significant role. Innovation can be driven by focusing on developing multi-target drugs and leveraging biotechnology to enhance the efficacy of existing treatments. Moreover, enhancing infection control measures and patient education can minimize MRSA transmission, indirectly impacting market growth. The nature of the MRSA drugs market is dynamic, with rapid advancements in medical research contributing to a constantly evolving landscape. Strategic investment in R&D and embracing cutting-edge technology will be essential for companies to establish a strong foothold and respond effectively to emerging threats posed by MRSA.

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.21 billion
Forecast Year [2030] USD 3.22 billion
CAGR (%) 6.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Methicillin-Resistant Staphylococcus Aureus Drugs Market

The Methicillin-Resistant Staphylococcus Aureus Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of infections associated with methicillin-resistant staphylococcus aureus
    • Rising investment in healthcare sector by private & public sector
  • Market Restraints
    • Fluctuating cost of raw materials used in methicillin-resistant staphylococcus aureus drugs formulations
  • Market Opportunities
    • Ongoing research & development activities to develop novel methicillin-resistant staphylococcus aureus drugs
    • Increasing number of patent expiration of methicillin-resistant staphylococcus aureus drugs
  • Market Challenges
    • Time consuming and strict regulatory approval processes

Porter's Five Forces: A Strategic Tool for Navigating the Methicillin-Resistant Staphylococcus Aureus Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Methicillin-Resistant Staphylococcus Aureus Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Methicillin-Resistant Staphylococcus Aureus Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

A detailed market share analysis in the Methicillin-Resistant Staphylococcus Aureus Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Methicillin-Resistant Staphylococcus Aureus Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

A strategic analysis of the Methicillin-Resistant Staphylococcus Aureus Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Methicillin-Resistant Staphylococcus Aureus Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Aridis Pharmaceuticals Inc., Armata Pharmaceuticals, Inc., AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bausch Health Companies Inc., Baxter International Inc., Becton, Dickinson and Company, Cardinal Health, Inc., Cumberland Pharmaceuticals Inc., Debiopharm SA, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, GlaxoSmithKline PLC, Innovation Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Nabriva Therapeutics GMBH, Novartis AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., R-Biopharm AG, Shionogi Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries ltd, and Theravance Biopharma, Inc..

Market Segmentation & Coverage

This research report categorizes the Methicillin-Resistant Staphylococcus Aureus Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Agent Type, market is studied across Ceftaroline, Daptomycin, Linezolid, Telavancin, and Vancomycin.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Sales Channel, market is studied across Offline and Online. The Offline is further studied across Hospitals Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infections associated with methicillin-resistant staphylococcus aureus
      • 5.1.1.2. Rising investment in healthcare sector by private & public sector
    • 5.1.2. Restraints
      • 5.1.2.1. Fluctuating cost of raw materials used in methicillin-resistant staphylococcus aureus drugs formulations
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research & development activities to develop novel methicillin-resistant staphylococcus aureus drugs
      • 5.1.3.2. Increasing number of patent expiration of methicillin-resistant staphylococcus aureus drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming and strict regulatory approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Agent Type: Evolving adoption of daptomycin for effective treatment of MRSA
    • 5.2.2. Sales Channel: Expanding preference towards online channels due to easy access
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Agent Type

  • 6.1. Introduction
  • 6.2. Ceftaroline
  • 6.3. Daptomycin
  • 6.4. Linezolid
  • 6.5. Telavancin
  • 6.6. Vancomycin

7. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.2.1. Hospitals Pharmacies
    • 8.2.2. Retail Pharmacies
  • 8.3. Online

9. Americas Methicillin-Resistant Staphylococcus Aureus Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. UK Government's Strategic Investment in Global AMR Surveillance, Strengthening Health Systems Across Asia and Africa
    • 12.3.2. Basilea Seeks FDA Approval for New MRSA-Fighting Antibiotic Ceftobiprole
    • 12.3.3. BARDA's Strategic Funding Initiative for Melinta Therapeutics to Enhance Pediatric Antibiotic Access
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Aridis Pharmaceuticals Inc.
  • 3. Armata Pharmaceuticals, Inc.
  • 4. AstraZeneca PLC
  • 5. Basilea Pharmaceutica Ltd.
  • 6. Bausch Health Companies Inc.
  • 7. Baxter International Inc.
  • 8. Becton, Dickinson and Company
  • 9. Cardinal Health, Inc.
  • 10. Cumberland Pharmaceuticals Inc.
  • 11. Debiopharm SA
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fresenius Kabi AG
  • 15. GlaxoSmithKline PLC
  • 16. Innovation Pharmaceuticals Inc.
  • 17. Johnson & Johnson Services, Inc.
  • 18. Lupin Limited
  • 19. Merck & Co., Inc.
  • 20. Nabriva Therapeutics GMBH
  • 21. Novartis AG
  • 22. Paratek Pharmaceuticals, Inc.
  • 23. Pfizer Inc.
  • 24. R-Biopharm AG
  • 25. Shionogi Inc.
  • 26. Takeda Pharmaceutical Company Limited
  • 27. Teva Pharmaceutical Industries ltd
  • 28. Theravance Biopharma, Inc.

LIST OF FIGURES

  • FIGURE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TELAVANCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 190. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023